Participant flow

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma · Source last updated 2025-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies

   id

   FG000

   title

   Group I (auto HSCT tbo-filgrastim)

2. description

   Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies

   id

   FG001

   title

   Group II (auto HSCT)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         9

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         38

      2. group Id

         FG001

         num Subjects

         39

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         32

      2. group Id

         FG001

         num Subjects

         30

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice